Drugs / Lanraplenib
Lanraplenib
also known as
LANRA · GS-SYK · GS-SYK Succinate · Lanraplenib sesquisuccinate · LANRAPLENIB SUCCINATE
Small molecule targets SYK via inhibition
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02959138 | Nov 2016 → Oct 2018 | inflammatory disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05028751 | Aug 2022 → Apr 2024 | acute myeloid leukemia | Kronos Bio | Terminated | No outcome recorded Stop: Business |
| Phase 23 trials · 2 missed | ||||||
| Phase 2 | NCT03285711 | Oct 2017 → May 2019 | lupus nephritis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03134222 | May 2017 → Mar 2019 | cutaneous lupus erythematosus | Gilead Sciences | Completed | Missed primary |
| Phase 2 | NCT03100942 | May 2017 → Jan 2019 | Sjogren syndrome | Gilead Sciences | Completed | Missed primary |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lanraplenib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05028751 ↗ |
| Known as | GS-SYK | ChEMBL registry synonym — accepted as the source's own label CHEMBL3986824 ↗ |
| Known as | GS-SYK Succinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3986824 ↗ |
| Known as | LANRA | “The primary objective of this study is to evaluate the safety of lanraplenib (LANRA) in combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in...” NCT05028751 ↗1“lanraplenib (LANRA), a spleen kinase inhibitor” PMID 34498056 ↗ May 2022 |
| Known as | Lanraplenib sesquisuccinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3986824 ↗ |
| Known as | LANRAPLENIB SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3986824 ↗ |
| Action | Inhibit | “lanraplenib 30 mg (spleen tyrosine kinase inhibitor)” PMID 35377447 ↗ Nov 2022 |
| Modality | Small molecule | — CHEMBL3986824 ↗ |
| Route | Oral | “administered orally” NCT02959138 ↗ |
| Target | SYK | “spleen kinase inhibitor” PMID 34498056 ↗ May 2022 |